Traders should monitor the AACR presentations for signs of strong preclinical efficacy or safety differentiation in HMPL-A580, which could boost sentiment. However, absence of clinical data limits immediate upside; surufatinib combination updates may influence near-term positioning in pancreatic and GI cancers.
HCM drugs
HCM drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 10 $15.24entry
- T+1 · 7mo ago +0.26%α −0.71% · $15.28
- T+5 · 7mo ago +3.28%α −1.23% · $15.74
- T+20 · 6mo ago −13.85%α −22.40% · $13.13
- T+60 · 4mo ago −27.03%α −36.74% · $11.12
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
HUTCHMED announced upcoming presentations of preclinical data for HMPL-A580, a first-in-class antibody-targeted therapy conjugate (ATTC), and updated clinical results for surufatinib combinations at the AACR 2026 meeting. The data highlight the novel mechanism and anti-tumor activity of HMPL-A580 in EGFR-expressing tumors and provide updates on ongoing trials in gastrointestinal and pancreatic cancers.
Key Facts
- Preclinical data for HMPL-A580, a first-in-class PI3K/PIKK-EGFR ATTC, will be presented at AACR 2026, showing potent and selective inhibition of tumor cell proliferation in EGFR-expressing models.
- HMPL-A580 demonstrated dose-dependent anti-tumor activity in xenograft models and favorable pharmacokinetics in monkeys, supporting its potential as a targeted therapy with improved safety over existing PAM inhibitors.
- Updated Phase Ib/II data for surufatinib plus sintilimab and capecitabine in metastatic small bowel and appendiceal carcinoma will be presented.
- Exploratory Phase II data on surufatinib combined with gemcitabine/nab-paclitaxel in pancreatic cancer following induction therapy will also be shared.
- No new clinical efficacy or safety data from human trials for HMPL-A580 were disclosed; all findings remain preclinical.
Financial Impact
Potential long-term value in oncology pipeline expansion, but no near-term revenue impact; HMPL-A580 remains preclinical
Risk Factors
- HMPL-A580 is in preclinical stage; clinical development risks include safety, tolerability, and lack of efficacy in humans.
- Combination therapies involving surufatinib rely on drugs not controlled by HUTCHMED, creating supply and regulatory dependency risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3270617 |
Track record
33 reports on HCM
8 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +38.35% at T+60 after the Jun 25, 2026 report. 18 of 23 went positive at some point.
Filters
- Nov 15, 20261d ago Press Release Neutral 4/10 Entry $14.90 Now $14.73 −1.14% settles Feb 12
- Nov 5, 202611d ago 6-K Bullish 5/10 Entry $14.20 Now $14.73 +3.73% settles Feb 3
- Nov 2, 202614d ago 6-K Bullish 6/10 Entry $13.27 Now $14.73 +11.00% settles Jan 29
- Nov 2, 202615d ago Press Release Bullish 6/10 Entry $13.08 Now $14.73 +12.61% settles Feb 1
- Oct 29, 202618d ago 6-K Neutral 4/10 Entry $13.59 Now $14.73 +8.39% settles Jan 27
- Oct 27, 202620d ago 6-K Neutral 2/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 26, 202621d ago 6-K Bullish 6/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202621d ago Press Release Bullish 7/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202622d ago Press Release Bullish 7/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $14.37 Now $14.73 +2.51% settles Jan 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers